JP2025508317A5 - - Google Patents
Info
- Publication number
- JP2025508317A5 JP2025508317A5 JP2024543273A JP2024543273A JP2025508317A5 JP 2025508317 A5 JP2025508317 A5 JP 2025508317A5 JP 2024543273 A JP2024543273 A JP 2024543273A JP 2024543273 A JP2024543273 A JP 2024543273A JP 2025508317 A5 JP2025508317 A5 JP 2025508317A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- seq
- amino acid
- acid sequence
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210068506.0 | 2022-01-20 | ||
| CN202210068506 | 2022-01-20 | ||
| PCT/CN2023/072510 WO2023138551A1 (zh) | 2022-01-20 | 2023-01-17 | 抗cd3和抗cd20双特异性抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508317A JP2025508317A (ja) | 2025-03-26 |
| JP2025508317A5 true JP2025508317A5 (enExample) | 2025-05-12 |
Family
ID=87183066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543273A Pending JP2025508317A (ja) | 2022-01-20 | 2023-01-17 | 抗ｃｄ３及び抗ｃｄ２０二重特異性抗体、並びにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250154275A1 (enExample) |
| EP (1) | EP4467571A4 (enExample) |
| JP (1) | JP2025508317A (enExample) |
| KR (1) | KR20240137640A (enExample) |
| CN (1) | CN116462765A (enExample) |
| AU (1) | AU2023209012A1 (enExample) |
| CA (1) | CA3249231A1 (enExample) |
| WO (1) | WO2023138551A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| WO2025131075A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3和抗cd3多特异性抗体及用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2017210485A1 (en) * | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| CN110603266A (zh) * | 2016-06-02 | 2019-12-20 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体 |
| MX2019006954A (es) * | 2016-12-20 | 2019-08-01 | Hoffmann La Roche | Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137). |
| CN108059680B (zh) * | 2017-12-26 | 2020-07-24 | 北京东方百泰生物科技有限公司 | 一种针对cd20和cd3的双特异性抗体 |
| US12460000B2 (en) * | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
| JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| CN112955471B (zh) * | 2018-12-07 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | Cd3抗体及其药物用途 |
| WO2020156405A1 (en) * | 2019-01-28 | 2020-08-06 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel bispecific cd3/cd20 polypeptide complexes |
| CN115894701A (zh) * | 2021-09-30 | 2023-04-04 | 上海君实生物医药科技股份有限公司 | 结合cd3的抗体及其用途 |
-
2023
- 2023-01-17 KR KR1020247027768A patent/KR20240137640A/ko active Pending
- 2023-01-17 CN CN202310071807.3A patent/CN116462765A/zh active Pending
- 2023-01-17 CA CA3249231A patent/CA3249231A1/en active Pending
- 2023-01-17 US US18/832,031 patent/US20250154275A1/en active Pending
- 2023-01-17 JP JP2024543273A patent/JP2025508317A/ja active Pending
- 2023-01-17 EP EP23742866.9A patent/EP4467571A4/en active Pending
- 2023-01-17 AU AU2023209012A patent/AU2023209012A1/en active Pending
- 2023-01-17 WO PCT/CN2023/072510 patent/WO2023138551A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018214223B2 (en) | Low pH pharmaceutical composition comprising T cell engaging antibody constructs | |
| JP2024036342A (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| US20240392003A1 (en) | Multispecific antibodies having specificity for ror1 and cd3 | |
| JP2021524478A5 (enExample) | ||
| EP3645741A2 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JP7611931B2 (ja) | ガイダンス及びナビゲーションコントロール（ｇｎｃ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP2022533538A5 (enExample) | ||
| JP2022111148A (ja) | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 | |
| TW202334204A (zh) | 條件性活化之抗原結合多肽複合物及其使用方法 | |
| EP4155318A1 (en) | Bispecific antibody and use thereof | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| KR20220167331A (ko) | 항-flt3 항체 및 조성물 | |
| CN119816523A (zh) | 抗Nectin-4抗体和包含其的多特异性抗体 | |
| WO2021167885A1 (en) | Cd137 binding molecules and uses thereof | |
| JP2025516590A5 (enExample) | ||
| WO2023180346A1 (en) | Deimmunized antibodies specific for cd3 | |
| EP4717714A1 (en) | Anti-pd-1-anti-vegf bispecific antibody, pharmaceutical composition thereof and use thereof | |
| CN118369340A (zh) | 一种双特异性抗原结合蛋白 | |
| TW202333788A (zh) | 一種抗ｔｎｆｒ２抗體藥物組合物 | |
| WO2025162198A1 (zh) | 双抗细胞因子融合蛋白及其用途 | |
| RU2025119828A (ru) | Связывающие белки, связывающие pd-1×4-1bb | |
| EP4676972A1 (en) | Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof | |
| CN119285769A (zh) | 多特异性抗体及其医药用途 | |
| HK40112840A (zh) | 抗cd19抗体及其使用和制备方法 |